FGFR1 abrogates inhibitory effect of androgen receptor concurrent with induction of androgen-receptor variants in androgen receptor-negative prostate tumor epithelial cells

Prostate

Volumn 71, Issue 15, 2011, Pages 1691-1700

  Kobayashi, Masashi ^a,b,c   Huang, Yanqing ^a   Jin, Chengliu ^a   Luo, Yongde ^a   Okamoto, Tetsuji ^b   Wang, Fen ^a   McKeehan, Wallace L ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b HIROSHIMA UNIVERSITY   (Japan)

^c ONOMICHI GENERAL HOSPITAL   (Japan)

Author keywords

castration resistance; fibroblast growth factor signaling; stem cells; tumor suppression; tyrosine kinases

Indexed keywords

ANDROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2 3B; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL POPULATION; DNA SYNTHESIS; GENE EXPRESSION; IMMUNOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; RAT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RATS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 79959295688     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21386     Document Type: Article

References (47)

1. Scher HI, Sawyers CL,. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23 (32): 8253-8261. (Pubitemid 46211563)
2. Shen MM, Abate-Shen C,. Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev 2010; 24 (18): 1967-2000.
3. Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C,. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 2010; 29 (25): 3593-3604.
4. Mathew P,. Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: The case for a prospective trial. Ann Oncol 2008; 19 (2): 395-396. (Pubitemid 351201727)
5. Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI,. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol 2009; 56 (2): 237-244.
6. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr., The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349 (3): 215-224. (Pubitemid 36859473)
7. Banach-Petrosky W, Jessen WJ, Ouyang X, Gao H, Rao J, Quinn J, Aronow BJ, Abate-Shen C,. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res 2007; 67 (19): 9089-9096. (Pubitemid 47535894)
8. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S, Chang C,. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105 (34): 12182-12187.
9. Niu Y, Altuwaijri S, Yeh S, Lai KP, Yu S, Chuang KH, Huang SP, Lardy H, Chang C,. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci USA 2008; 105 (34): 12188-12193.
10. Yan G, McBride G, McKeehan WL,. Exon skipping causes alteration of the COOH-terminus and deletion of the phospholipase C gamma 1 interaction site in the FGF receptor 2 kinase in normal prostate epithelial cells. Biochem Biophys Res Commun 1993; 194 (1): 512-518. (Pubitemid 23237965)
11. Feng S, Wang F, Matsubara A, Kan M, McKeehan WL,. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res 1997; 57 (23): 5369-5378. (Pubitemid 27516376)
12. McKeehan WL, Wang F, Kan M,. The heparan sulfate-fibroblast growth factor family: Diversity of structure and function. Prog Nucleic Acid Res Mol Biol 1998; 59: 135-176.
13. Jin C, Wang F, Wu X, Yu C, Luo Y, McKeehan WL,. Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumors. Cancer Res 2004; 64 (13): 4555-4562. (Pubitemid 38856928)
14. McKeehan WL, Wang F, Luo Y,. The fibroblast growth factor (FGF) signaling complex. In:, Bradshaw R, Dennis E, editors. Handbook of cell signaling, 2nd edition. Oxford: Academic Press; 2009. p 253-259.
15. Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL,. Heparin-binding keratinocyte growth factor is a candidate stromal-to epithelial-cell andromedin. Mol Endocrinol (Baltimore, MD) 1992; 6 (12): 2123-2128. (Pubitemid 23021561)
16. Lu W, Luo Y, Kan M, McKeehan WL,. Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 1999; 274 (18): 12827-12834.
17. Wu X, Jin C, Wang F, Yu C, McKeehan WL,. Stromal cell heterogeneity in fibroblast growth factor-mediated stromal-epithelial cell cross-talk in premalignant prostate tumors. Cancer Res 2003; 63 (16): 4936-4944. (Pubitemid 37022629)
18. Isaacs JT, Coffey DS,. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 1981; 41 (12 Pt 1): 5070-5075. (Pubitemid 12196676)
19. Quarmby VE, Beckman WC Jr, Cooke DB, Lubahn DB, Joseph DR, Wilson EM, French FS,. Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. Cancer Res 1990; 50 (3): 735-739. (Pubitemid 20054207)
20. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL,. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993; 13 (8): 4513-4522. (Pubitemid 23220358)
21. Wang F, McKeehan K, Yu C, McKeehan WL,. Fibroblast growth factor receptor 1 phosphotyrosine 766: Molecular target for prevention of progression of prostate tumors to malignancy. Cancer Res 2002; 62 (6): 1898-1903. (Pubitemid 34408519)
22. Matsubara A, Kan M, Feng S, McKeehan WL,. Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. Cancer Res 1998; 58 (7): 1509-1514. (Pubitemid 28193616)
23. Giri D, Ropiquet F, Ittmann M,. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999; 5 (5): 1063-1071. (Pubitemid 29233220)
24. Ozen M, Giri D, Ropiquet F, Mansukhani A, Ittmann M,. Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst 2001; 93 (23): 1783-1790. (Pubitemid 33150450)
25. Naimi B, Latil A, Fournier G, Mangin P, Cussenot O, Berthon P,. Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate 2002; 52 (3): 245-252. (Pubitemid 34791225)
26. Yasumoto H, Matsubara A, Mutaguchi K, Usui T, McKeehan WL,. Restoration of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells. Prostate 2004; 61 (3): 236-242. (Pubitemid 39350445)
27. Devilard E, Bladou F, Ramuz O, Karsenty G, Dales JP, Gravis G, Nguyen C, Bertucci F, Xerri L, Birnbaum D,. FGFR1 and WT1 are markers of human prostate cancer progression. BMC Cancer 2006; 6: 272.
28. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA,. Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Arch 2006; 448 (1): 668-674.
29. Sahadevan K, Darby S, Leung H, Mathers M, Robson C, Gnanapragasam V,. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007; 213 (1): 82-90. (Pubitemid 47354569)
30. Matsubara A, Teishima J, Mirkhat S, Yasumoto H, Mochizuki H, Seki M, Mutaguchi K, McKeehan WL, Usui T,. Restoration of FGF receptor type 2 enhances radiosensitivity of hormone-refractory human prostate carcinoma PC-3 cells. Anticancer Res 2008; 28 (4B): 2141-2146.
31. Foster BA, Kaplan PJ, Greenberg NM,. Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model. Prostate Cancer Prostate Dis 1999; 2 (2): 76-82. (Pubitemid 29259936)
32. Jin C, McKeehan K, Guo W, Jauma S, Ittmann MM, Foster B, Greenberg NM, McKeehan WL, Wang F,. Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate. Cancer Res 2003; 63 (24): 8784-8790. (Pubitemid 38064058)
33. Wang F, McKeehan K, Yu C, Ittmann M, McKeehan WL,. Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia. Prostate 2004; 58 (1): 1-12. (Pubitemid 38057983)
34. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M, Spencer DM,. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007; 12 (6): 559-571. (Pubitemid 350199071)
35. Lin Y, Liu G, Zhang Y, Hu YP, Yu K, Lin C, McKeehan K, Xuan JW, Ornitz DM, Shen MM, Greenberg N, McKeehan WL, Wang F,. Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis. Development 2007; 134 (4): 723-734. (Pubitemid 46437914)
36. McKeehan WL, Adams PS, Fast D,. Different hormonal requirements for androgen-independent growth of normal and tumor epithelial cells from rat prostate. In Vitro Cell Dev Biol 1987; 23 (2): 147-152.
37. Kan M, Shi EG, McKeehan WL,. Identification and assay of fibroblast growth factor receptors. Methods Enzymol 1991; 198: 158-171.
38. Yu C, Wang F, Kan M, Jin C, Jones RB, Weinstein M, Deng CX, McKeehan WL,. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 2000; 275 (20): 15482-15489. (Pubitemid 30337280)
39. Zhang J, Thomas TZ, Kasper S, Matusik RJ,. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000; 141 (12): 4698-4710. (Pubitemid 32055150)
40. Acevedo VD, Ittmann M, Spencer DM,. Paths of FGFR-driven tumorigenesis. Cell Cycle (Georgetown, TX) 2009; 8 (4): 580-588.
41. Litvinov IV, De Marzo AM, Isaacs JT,. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling ? J Clin Endocrinol Metab 2003; 88 (7): 2972-2982. (Pubitemid 36877458)
42. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL,. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010; 107 (39): 16759-16765.
43. Lawson DA, Witte ON,. Stem cells in prostate cancer initiation and progression. J Clin Invest 2007; 117 (8): 2044-2050. (Pubitemid 47219544)
44. Luo Y, Yang C, Jin C, Xie R, Wang F, McKeehan WL,. Novel phosphotyrosine targets of FGFR2IIIb signaling. Cell Signal 2009; 21 (9): 1370-1378.
45. Villegas SN, Canham M, Brickman JM,. FGF signalling as a mediator of lineage transitions-Evidence from embryonic stem cell differentiation. J Cell Biochem 110 (1): 10-20.
46. Lanner F, Rossant J,. The role of FGF/Erk signaling in pluripotent cells. Development 2010; 137 (20): 3351-3360.
47. Claessens F, Denayer S, Van Tilborgh N, Kerkhofs S, Helsen C, Haelens A,. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl Recept Signal 2008; 6: e008.